PROMIS NEUROSCIENCES INC (PMN) Stock Price & Overview
NASDAQ:PMN • CA74346M5054
Current stock price
The current stock price of PMN is 17.77 USD. Today PMN is up by 0.97%. In the past month the price increased by 12.54%. In the past year, price increased by 1.54%.
PMN Key Statistics
- Market Cap
- 38.206M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
PMN Stock Performance
PMN Stock Chart
PMN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PMN. When comparing the yearly performance of all stocks, PMN is one of the better performing stocks in the market, outperforming 94.87% of all stocks.
PMN Earnings
PMN Forecast & Estimates
8 analysts have analysed PMN and the average price target is 83 USD. This implies a price increase of 367.09% is expected in the next year compared to the current price of 17.77.
PMN Groups
Sector & Classification
PMN Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PMN Ownership
PMN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.81 | 362.599B | ||
| AMGN | AMGEN INC | 15.32 | 187.489B | ||
| GILD | GILEAD SCIENCES INC | 15.54 | 170.335B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.28 | 115.33B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.75 | 77.479B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.1 | 41.4B | ||
| INSM | INSMED INC | N/A | 29.315B | ||
| NTRA | NATERA INC | N/A | 27.677B | ||
| BIIB | BIOGEN INC | 11.42 | 26.631B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.45 | 22.979B | ||
| MRNA | MODERNA INC | N/A | 20.292B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.981B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PMN
Company Profile
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Company Info
IPO: 2017-04-03
PROMIS NEUROSCIENCES INC
Suite 200, 1920 Yonge Street
TORONTO ONTARIO CA
Employees: 6
Phone: 14168476898
PROMIS NEUROSCIENCES INC / PMN FAQ
What does PMN do?
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2017-04-03. The company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Can you provide the latest stock price for PROMIS NEUROSCIENCES INC?
The current stock price of PMN is 17.77 USD. The price increased by 0.97% in the last trading session.
Does PMN stock pay dividends?
PMN does not pay a dividend.
How is the ChartMill rating for PROMIS NEUROSCIENCES INC?
PMN has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Where is PROMIS NEUROSCIENCES INC (PMN) stock traded?
PMN stock is listed on the Nasdaq exchange.
What is the Short Interest ratio of PROMIS NEUROSCIENCES INC (PMN) stock?
The outstanding short interest for PROMIS NEUROSCIENCES INC (PMN) is 7.1% of its float.